Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

west pharmaceutical services inc. - WST

WST

Close Chg Chg %
279.06 1.60 0.57%

Closed Market

280.66

+1.60 (0.57%)

Volume: 1.07M

Last Updated:

Jan 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: west pharmaceutical services inc. - WST

WST Key Data

Open

$277.75

 Day Range

275.51 - 291.34

52 Week Range

187.43 - 348.90

 Market Cap

$19.89B

Shares Outstanding

71.94M

 Public Float

71.50M

Beta

1.17

 Rev. Per Employee

N/A

P/E Ratio

40.94

 EPS

$6.79

Yield

30.75%

 Dividend

$0.22

EX-DIVIDEND DATE

Jan 28, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

664.05K

  

WST Performance

1 Week
 
 2.07%
 
1 Month
 
 0.21%
 
3 Months
 
 7.28%
 
1 Year
 
 -15.34%
 
5 Years
 
 -8.68%
 

WST Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About west pharmaceutical services inc. - WST

West Pharmaceutical Services, Inc. engages in the manufacture and marketing of pharmaceuticals, biologics, vaccines, and consumer healthcare products. It operates through the Proprietary Products and Contract-Manufactured Products segments. The Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

WST At a Glance

West Pharmaceutical Services, Inc.
530 Herman O. West Drive
Exton, Pennsylvania 19341-1147
Phone 1-610-594-2900 Revenue 2.89B
Industry Medical Specialties Net Income 492.70M
Sector Health Technology Employees 10,600
Fiscal Year-end 12 / 2025
View SEC Filings

WST Valuation

P/E Current 40.94
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 48.998
Price to Sales Ratio 8.346
Price to Book Ratio 8.829
Price to Cash Flow Ratio 36.95
Enterprise Value to EBITDA 31.949
Enterprise Value to Sales 8.284
Total Debt to Enterprise Value 0.013

WST Efficiency

Revenue/Employee 272,896.226
Income Per Employee 46,481.132
Receivables Turnover 5.024
Total Asset Turnover 0.774

WST Liquidity

Current Ratio 2.795
Quick Ratio 2.11
Cash Ratio 0.88

WST Profitability

Gross Margin 34.646
Operating Margin 20.555
Pretax Margin 20.241
Net Margin 17.033
Return on Assets 13.186
Return on Equity 17.713
Return on Total Capital 16.491
Return on Invested Capital 16.404

WST Capital Structure

Total Debt to Total Equity 11.382
Total Debt to Total Capital 10.219
Total Debt to Total Assets 8.38
Long-Term Debt to Equity 10.681
Long-Term Debt to Total Capital 9.59
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for West Pharmaceutical Services Inc. - WST

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.83B 2.89B 2.95B 2.89B
Sales Growth
+31.86% +1.94% +2.27% -1.98%
Cost of Goods Sold (COGS) incl D&A
1.66B 1.75B 1.82B 1.89B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
122.30M 120.60M 137.30M 155.40M
Depreciation
116.90M 116.90M 133.70M 151.80M
Amortization of Intangibles
5.40M 3.70M 3.60M 3.60M
COGS Growth
+20.20% +5.39% +4.11% +3.97%
Gross Income
1.17B 1.14B 1.13B 1.00B
Gross Income Growth
+52.81% -2.94% -0.54% -11.52%
Gross Profit Margin
+41.45% +39.47% +38.38% +34.65%
2021 2022 2023 2024 5-year trend
SG&A Expense
414.70M 375.40M 421.80M 407.60M
Research & Development
52.80M 58.50M 68.40M 69.10M
Other SG&A
361.90M 316.90M 353.40M 338.50M
SGA Growth
+18.86% -9.48% +12.36% -3.37%
Other Operating Expense
- - - -
-
Unusual Expense
3.90M 36.20M 13.80M 19.00M
EBIT after Unusual Expense
754.80M 727.30M 697.10M 575.60M
Non Operating Income/Expense
2.60M (39.80M) 9.70M 12.80M
Non-Operating Interest Income
1.00M 5.10M 28.00M 19.60M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
8.50M 7.60M 8.80M 2.90M
Interest Expense Growth
- -10.59% +15.79% -67.05%
Gross Interest Expense
10.50M 11.30M 8.80M 16.10M
Interest Capitalized
- 2.00M 3.70M 13.20M
Pretax Income
748.90M 679.90M 698.00M 585.50M
Pretax Income Growth
+86.62% -9.21% +2.66% -16.12%
Pretax Margin
+26.46% +23.56% +23.65% +20.24%
Income Tax
107.20M 114.70M 122.30M 107.50M
Income Tax - Current - Domestic
75.70M 84.10M 26.00M 31.90M
Income Tax - Current - Foreign
74.40M 61.40M 58.80M 79.10M
Income Tax - Deferred - Domestic
7.30M (20.30M) (11.60M) (18.30M)
Income Tax - Deferred - Foreign
(50.20M) (10.50M) 49.10M 14.80M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
661.80M 585.90M 593.40M 492.70M
Minority Interest Expense
- - - -
-
Net Income
661.80M 585.90M 593.40M 492.70M
Net Income Growth
+91.16% -11.47% +1.28% -16.97%
Net Margin Growth
+23.38% +20.30% +20.11% +17.03%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
661.80M 585.90M 593.40M 492.70M
Preferred Dividends
- - - -
-
Net Income Available to Common
661.80M 585.90M 593.40M 492.70M
EPS (Basic)
8.8952 7.875 7.9865 6.7493
EPS (Basic) Growth
+89.88% -11.47% +1.42% -15.49%
Basic Shares Outstanding
74.40M 74.40M 74.30M 73.00M
EPS (Diluted)
8.6737 7.7296 7.8805 6.6852
EPS (Diluted) Growth
+89.91% -10.88% +1.95% -15.17%
Diluted Shares Outstanding
76.30M 75.80M 75.30M 73.70M
EBITDA
881.00M 884.10M 848.20M 750.00M
EBITDA Growth
+66.82% +0.35% -4.06% -11.58%
EBITDA Margin
+31.12% +30.64% +28.74% +25.93%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 349.786
Number of Ratings 20 Current Quarters Estimate 1.659
FY Report Date 03 / 2026 Current Year's Estimate 7.809
Last Quarter’s Earnings 1.838 Median PE on CY Estimate N/A
Year Ago Earnings 7.096 Next Fiscal Year Estimate 8.854
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 16 13
Mean Estimate 1.66 1.97 7.81 8.85
High Estimates 1.76 2.11 8.38 9.59
Low Estimate 1.56 1.91 7.45 8.52
Coefficient of Variance 3.60 2.61 2.73 3.72

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 12
OVERWEIGHT 3 3 2
HOLD 4 4 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for West Pharmaceutical Services Inc. - WST

Date Name Shares Transaction Value
Aug 13, 2025 Robert W. McMahon SVP & Chief Financial Officer 12,670 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Robert W. McMahon SVP & Chief Financial Officer 3,168 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Robert W. McMahon SVP & Chief Financial Officer 7,647 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Robert W. McMahon SVP & Chief Financial Officer 7,137 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Janet Brutschea Haugen Director 56 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Annette F. Favorite Sr. VP & Chief HR Officer 6,739 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $211 per share 1,421,929.00
Feb 21, 2025 Cindy Reiss-Clark Chief Commercial Officer 503 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Chad R. Winters VP, Chief Accounting Officer 1,391 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $211 per share 293,501.00
Feb 21, 2025 Bernard J. Birkett Sr VP, Chief Financial Officer 1,740 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Bernard J. Birkett Sr VP, Chief Financial Officer 4,020 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Bernard J. Birkett Sr VP, Chief Financial Officer 7,520 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $211 per share 1,586,720.00
Feb 21, 2025 Bernard J. Birkett Sr VP, Chief Financial Officer 7,556 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $211 per share 1,594,316.00
Feb 21, 2025 Bernard J. Birkett Sr VP, Chief Financial Officer 7,431 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $211 per share 1,567,941.00
Feb 21, 2025 Bernard J. Birkett Sr VP, Chief Financial Officer 7,669 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $211 per share 1,618,159.00
Feb 21, 2025 Annette F. Favorite Sr. VP & Chief HR Officer 542 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Annette F. Favorite Sr. VP & Chief HR Officer 1,251 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Eric Mark Green President, CEO and Board Chair; Director 170,369 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $211 per share 35,947,859.00
Feb 21, 2025 Annette F. Favorite Sr. VP & Chief HR Officer 6,823 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $211 per share 1,439,653.00
Feb 21, 2025 Eric Mark Green President, CEO and Board Chair; Director 5,256 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Eric Mark Green President, CEO and Board Chair; Director 12,149 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

West Pharmaceutical Services Inc. in the News